176 related articles for article (PubMed ID: 21756025)
1. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Chen WC; Sigal DS; Saven A; Paulson JC
Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
[TBL] [Abstract][Full Text] [Related]
2. In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
Chen WC; Completo GC; Sigal DS; Crocker PR; Saven A; Paulson JC
Blood; 2010 Jun; 115(23):4778-86. PubMed ID: 20181615
[TBL] [Abstract][Full Text] [Related]
3. CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.
Peng W; Paulson JC
J Am Chem Soc; 2017 Sep; 139(36):12450-12458. PubMed ID: 28829594
[TBL] [Abstract][Full Text] [Related]
4. Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.
Hong S; Yu C; Wang P; Shi Y; Cao W; Cheng B; Chapla DG; Ma Y; Li J; Rodrigues E; Narimatsu Y; Yates JR; Chen X; Clausen H; Moremen KW; Macauley MS; Paulson JC; Wu P
Angew Chem Int Ed Engl; 2021 Feb; 60(7):3603-3610. PubMed ID: 33314603
[TBL] [Abstract][Full Text] [Related]
5. Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy.
Madge PD; Maggioni A; Pascolutti M; Amin M; Waespy M; Bellette B; Thomson RJ; Kelm S; von Itzstein M; Haselhorst T
Sci Rep; 2016 Nov; 6():36012. PubMed ID: 27808110
[TBL] [Abstract][Full Text] [Related]
6. Siglecs as targets for therapy in immune-cell-mediated disease.
O'Reilly MK; Paulson JC
Trends Pharmacol Sci; 2009 May; 30(5):240-8. PubMed ID: 19359050
[TBL] [Abstract][Full Text] [Related]
7. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking.
Han S; Collins BE; Bengtson P; Paulson JC
Nat Chem Biol; 2005 Jul; 1(2):93-7. PubMed ID: 16408005
[TBL] [Abstract][Full Text] [Related]
8. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.
O'Reilly MK; Tian H; Paulson JC
J Immunol; 2011 Feb; 186(3):1554-63. PubMed ID: 21178016
[TBL] [Abstract][Full Text] [Related]
9. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
10. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Collins BE; Blixt O; Han S; Duong B; Li H; Nathan JK; Bovin N; Paulson JC
J Immunol; 2006 Sep; 177(5):2994-3003. PubMed ID: 16920935
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
12. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
13. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
14. Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man.
Macauley MS; Kawasaki N; Peng W; Wang SH; He Y; Arlian BM; McBride R; Kannagi R; Khoo KH; Paulson JC
J Biol Chem; 2015 Dec; 290(50):30066-77. PubMed ID: 26507663
[TBL] [Abstract][Full Text] [Related]
15. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
16. Identification of Siglec Cis-Ligands by Proximity Labeling.
Alborzian Deh Sheikh A; Akatsu C; Tsubata T
Methods Mol Biol; 2020; 2132():75-83. PubMed ID: 32306316
[TBL] [Abstract][Full Text] [Related]
17. Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies.
Kim B; Shin J; Kiziltepe T; Bilgicer B
Nanoscale; 2020 Jun; 12(21):11672-11683. PubMed ID: 32436925
[TBL] [Abstract][Full Text] [Related]
18. In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.
Ramya TN; Weerapana E; Liao L; Zeng Y; Tateno H; Liao L; Yates JR; Cravatt BF; Paulson JC
Mol Cell Proteomics; 2010 Jun; 9(6):1339-51. PubMed ID: 20172905
[TBL] [Abstract][Full Text] [Related]
19. New Human CD22/Siglec-2 Ligands with a Triazole Glycoside.
Prescher H; Schweizer A; Kuhfeldt E; Nitschke L; Brossmer R
Chembiochem; 2017 Jul; 18(13):1216-1225. PubMed ID: 28374962
[TBL] [Abstract][Full Text] [Related]
20. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
Nitschke L
Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
